Extended Data Table 2.
Grade 3 and 4 toxicities from phase I clinical trial of RT + anti-CTLA4 for metastatic melanoma.
Two dose levels in two strata were tested. Stratum 1 (lung/bone) utilized 8 Gy x 2 or 8 Gy x 3. Stratum 2 (liver/subcutaneous) utilized 6 Gy x 2 or 6 Gy x 3. Six patients for each dose level were planned. All dose levels met accrual except 8 Gy x 3 prior to trial closure.
| Radiation Dose | |||||
|---|---|---|---|---|---|
|
| |||||
| Grade 3 Toxicities* | 6Gy x 2 | 8Gy x 2 | 6Gy x 3 | 8Gy x 3 | |
| n=6 | n=6 | n=6 | n=4 | Total | |
| Edema | 1 | 1 | |||
| Anaphylaxis | 1 | 1 | |||
| Hypotension | 1 | 1 | |||
| Fatigue | 1 | 1 | |||
| Anemia | 2 | 1 | 1 | 4 | |
| Gastric hemorrhage | 1 | 1 | |||
| Wound infection | 1 | 1 | |||
| Diarrhea | 1 | 1 | |||
| Cholecystitis | 1 | 1 | |||
| Weight loss | 1 | 1 | |||
| Colitis | 1 | 1 | |||
| Pneumothorax | 1 | 1 | |||
*
No Grade 4 toxicities were observed